Avalo Therapeutics, Inc.
AVTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -77.1% | -89.3% | 234.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 183% | 33.3% | 81% | 72.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -15,497.3% | -1,210.3% | -206.5% | -1,490.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -7,965.8% | -1,639.5% | -230.8% | -1,563.1% |
| EPS Diluted | -3.26 | -113.58 | -1,062.65 | -2,330.66 |
| % Growth | 97.1% | 89.3% | 54.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |